{"id":"W2564893835","doi":"10.1093/annonc/mdw372.09","title":"Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Prostate cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Cohort; Adenocarcinoma; Cancer; Prostate; Clinical trial; Phases of clinical research; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002309424,0.0009422227,0.001456206,0.0002125924,0.0003557535,0.0009927546,0.0006165495,0.0006634485,0.001938017],"category_scores_gemma":[0.001803792,0.0003506737,0.001346851,0.000586,0.0004116909,0.001034043,0.0005279807,0.001903219,0.0004887948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007201713,"about_ca_system_score_gemma":0.0008786567,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001261885,"about_ca_topic_score_gemma":0.003339177,"domain_scores_codex":[0.9992725,0.000387869,0.00003690488,0.0001100502,0.00008331321,0.0001093543],"domain_scores_gemma":[0.9989467,0.0002974379,0.000268934,0.0001011239,0.00007667535,0.0003091458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6761721,0.01061844,0.122614,0.001857428,0.0117198,0.0005796441,0.0003711297,0.002302055,0.0240535,0.0003485052,0.007808281,0.1415552],"study_design_scores_gemma":[0.3462002,0.1510911,0.4645371,0.0002569557,0.01434594,0.0009085935,0.0003612455,0.001553546,0.004187715,0.0007144675,0.01573396,0.0001092045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891026,0.005067262,0.0002545569,0.000682262,0.00008037988,0.0003498754,0.002029418,0.00002099547,0.002412625],"genre_scores_gemma":[0.991336,0.002843,0.0005284727,0.0007423441,0.0001741726,0.0002726396,0.003150501,0.00001381835,0.0009389825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002309424,"threshold_uncertainty_score":0.01221359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04219005847890556,"score_gpt":0.3388457222291932,"score_spread":0.2966556637502877,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}